ReviewFrontiers in microbiology2022
Current Therapy and Therapeutic Targets for Microsporidiosis.
Review in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- A global overview of microsporidia infection in HIV/AIDS patients: an updated systematic review and meta-analysis.International health · 2026Pooled it
- Bilateral Encephalitozoon hellem Keratoconjunctivitis With Microsporidial Spores in Parrot Feces.Cureus · 2026Article
- First joint report on the prevalence and genotyping of Cryptosporidium spp., Giardia duodenalis, and Enterocytozoon bieneusi among hospitalized children in Inner Mongolia, China.BMC infectious diseases · 2026Article
- Prevalence and Multi-Locus Genotyping ofAnimals : an open access journal from MDPI · 2026Article
- The Effect of Elaeagnus angustifolia L. Leaf Extract on Encephalitozoon intestinalis, Acanthamoeba castellanii, and Leishmania major.Acta parasitologica · 2026Article
- Identification of natural products and synthetic analogs which inhibit microsporidia spores and prevent infection.Journal of invertebrate pathology · 2026Article
- Encephalitozoonosis in Pet Rabbits: Epidemiology, Pathogenesis, Immunology and Consensus on Clinical Management.Animals : an open access journal from MDPI · 2026Review
- Confronting the known unknown: historical lessons and future strategies for Disease X.Frontiers in public health · 2026Review
- Microsporidium Keratitis After Hurricane Francine: A Case Report.Case reports in ophthalmological medicine · 2026Article
- Integrative High-Throughput Screening and Microscopic Evidence Implicates Microsporidia as a Potential Pathogen of "Pus Crab" in the Mud Crab (Animals : an open access journal from MDPI · 2025Article
- Small-molecule screen in C. elegans identifies benzenesulfonamides as inhibitors of microsporidia spores.npj antimicrobials and resistance · 2025Article
- Therapeutic Potential of Propolis and Royal Jelly in Encephalitozoon Intestinalis Infection: An in Vitro Study.Acta parasitologica · 2025Article
- Establishment and application of a loop-mediated isothermal amplification method based onFrontiers in veterinary science · 2025Article
- Natural terpenoids with therapeutic potential against pulmonary arterial hypertension.Frontiers in pharmacology · 2025Review
- Transgenic overexpression of bmo-miR-6498-5p increases resistance toApplied and environmental microbiology · 2024Article
- The Zoonotic Potential of Fungal Pathogens: Another Dimension of the One Health Approach.Diagnostics (Basel, Switzerland) · 2024Review
- The first evaluation of the in vitro effects of silver(I)-N-heterocyclic carbene complexes on Encephalitozoon intestinalis and Leishmania major promastigotes.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2024Article
- Treatment of MicrosporidiumMicroorganisms · 2024Article
- Molecular characterization and phylogenetic analyses of MetAP2 gene and protein ofFrontiers in veterinary science · 2024Article
- Screening of the Pandemic Response Box identifies anti-microsporidia compounds.PLoS neglected tropical diseases · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
Microsporidia are obligate intracellular, spore-forming parasitic fungi which are grouped with the Cryptomycota. They are both opportunistic pathogens in humans and emerging veterinary pathogens. In humans, they cause chronic diarrhea in immune-compromised patients and infection is associated with increased mortality. Besides their role in pébrine in sericulture, which was described in 1865, the prevalence and severity of microsporidiosis in beekeeping and aquaculture has increased markedly in recent decades. Therapy for these pathogens in medicine, veterinary, and agriculture has become a recent focus of attention. Currently, there are only a few commercially available antimicrosporidial drugs. New therapeutic agents are needed for these infections and this is an active area of investigation. In this article we provide a comprehensive summary of the current as well as several promising new agents for the treatment of microsporidiosis including: albendazole, fumagillin, nikkomycin, orlistat, synthetic polyamines, and quinolones. Therapeutic targets which could be utilized for the design of new drugs are also discussed including: tubulin, type 2 methionine aminopeptidase, polyamines, chitin synthases, topoisomerase IV, triosephosphate isomerase, and lipase. We also summarize reports on the utility of complementary and alternative medicine strategies including herbal extracts, propolis, and probiotics. This review should help facilitate drug development for combating microsporidiosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.